<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Nordic Bioscience</provider_name><provider_url>https://www.nordicbioscience.com</provider_url><author_name>Claire Hornung</author_name><author_url>https://www.nordicbioscience.com/blog/author/claire-h/</author_url><title>Longitudinal Stability of Molecular Endotypes of Knee Osteoarthritis Patients</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="geQTh1hgU4"&gt;&lt;a href="https://www.nordicbioscience.com/blog/longitudinal-stability-of-molecular-endotypes-of-knee-osteoarthritis-patients/"&gt;Longitudinal Stability of Molecular Endotypes of Knee Osteoarthritis Patients&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.nordicbioscience.com/blog/longitudinal-stability-of-molecular-endotypes-of-knee-osteoarthritis-patients/embed/#?secret=geQTh1hgU4" width="600" height="338" title="&#x201C;Longitudinal Stability of Molecular Endotypes of Knee Osteoarthritis Patients&#x201D; &#x2014; Nordic Bioscience" data-secret="geQTh1hgU4" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
&lt;/script&gt;
</html><thumbnail_url>https://www.nordicbioscience.com/wp-content/uploads/2025/07/osteoarthritis-biomarkers-nordic-bioscience.webp</thumbnail_url><thumbnail_width>602</thumbnail_width><thumbnail_height>401</thumbnail_height><description>There are more than 500 million people worldwide who are affected by osteoarthritis (OA) and left without effective treatment options. Despite significantly different etiologies, clinical trial designs for evaluation of novel treatments still do not typically involve patient selection based on pheno- or endotypic traits. This has likely contributed to the lack of approved disease-modifying [&hellip;]</description></oembed>
